OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Apr 8, 2024 • 9min
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.
Apr 1, 2024 • 14min
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.
Mar 28, 2024 • 15min
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant disease.
Mar 25, 2024 • 35min
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.
Mar 21, 2024 • 14min
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
Mar 18, 2024 • 14min
S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Dr Lunning sits down with Alex Herrera, MD, of City of Hope, to discuss the frontline management of Hodgkin lymphoma, including the rationale for the SWOG 1826 trial, the collaborative efforts between pediatric and adult oncologists that led to the successful initiation of this trial, potential future directions for this research, and more.
Mar 11, 2024 • 7min
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.
Mar 7, 2024 • 11min
S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
Dr Kyriakopoulos sheds light on the potential synergy and pharmacokinetic interactions between masofaniten and enzalutamide when used in combination for patients with prostate cancer; contextualizes safety and pharmacokinetic findings from the phase 1 portion of a phase 1/2 study; and outlines key objectives of the agent’s ongoing evaluation in the phase 2 portion of the study.
Feb 29, 2024 • 9min
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusion on UCSF’s formulary, and the debate around Epstein-Barr virus as a selection criteria for treatment eligibility.
Feb 26, 2024 • 10min
S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.
